Statements (121)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:administered_by |
gptkb:capsule
oral tablet |
| gptkbp:approves |
gptkb:1957
gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:atccode |
L01 XX32
|
| gptkbp:available_on |
oral tablet
|
| gptkbp:brand |
gptkb:Thalomid
|
| gptkbp:casnumber |
50-35-1
|
| gptkbp:cause |
birth defects
|
| gptkbp:caused_by |
birth defects
|
| gptkbp:chemical_formula |
C13 H10 N2 O4 S
|
| gptkbp:class |
immunomodulatory drug
|
| gptkbp:clinical_trial |
Phase IV
Phase II Phase III Phase I |
| gptkbp:contraindication |
pregnancy
breastfeeding |
| gptkbp:developed_by |
gptkb:Chemie_Grünenthal
|
| gptkbp:discovered_by |
gptkb:Germany
1950s |
| gptkbp:excretion |
urine
feces |
| gptkbp:historical_significance |
caused regulatory changes in drug approval processes
influenced drug safety legislation led to the establishment of the FDA's pregnancy category system |
| https://www.w3.org/2000/01/rdf-schema#label |
Thalidomide
|
| gptkbp:invention |
patented
generic available |
| gptkbp:is_a |
sedative
immunomodulatory drug |
| gptkbp:is_a_drug_that |
modulates immune response
has a complex history requires careful monitoring has a legacy of caution has been re-evaluated for use has both supporters and critics has undergone significant scrutiny |
| gptkbp:is_a_drug_that_can |
cause teratogenic effects
|
| gptkbp:is_a_subject_of |
gptkb:medical_research
|
| gptkbp:is_associated_with |
gptkb:deep_vein_thrombosis
fatigue rash peripheral neuropathy pulmonary embolism severe side effects |
| gptkbp:is_known_for |
controversial history
anti-inflammatory effects teratogenic effects anti-angiogenic properties immunomodulatory properties revival in modern medicine causing limb deformities |
| gptkbp:is_linked_to |
severe disabilities
|
| gptkbp:is_part_of |
HIV/ AIDS treatment
cancer treatment regimens cancer therapy regimens graft-versus-host disease treatment inflammatory disease treatment thalidomide therapy |
| gptkbp:is_subject_to |
strict regulations
monitoring programs risk evaluation and mitigation strategies |
| gptkbp:is_used_for |
gptkb:Oncology
|
| gptkbp:is_used_in |
gptkb:cancer_treatment
clinical trials autoimmune diseases the 1960s |
| gptkbp:is_used_in_the_treatment_of |
leprosy
|
| gptkbp:is_used_in_treatment_for |
HIV-related conditions
|
| gptkbp:legal_status |
prescription only
|
| gptkbp:lifespan |
5 to 7 hours
|
| gptkbp:market_position |
gptkb:1961
|
| gptkbp:marketed_as |
gptkb:Celgene_Corporation
gptkb:1957 gptkb:Bristol-Myers_Squibb gptkb:Thalomid safe for pregnant women treatment of insomnia treating insomnia treating morning sickness treatment of morning sickness Contergan |
| gptkbp:mechanism_of_action |
inhibits TNF-alpha production
immunomodulatory |
| gptkbp:metabolism |
liver
|
| gptkbp:produced_by |
pharmaceutical companies
|
| gptkbp:reintroduced_for |
gptkb:cancer_treatment
HIV-related conditions |
| gptkbp:related_to |
gptkb:lenalidomide
gptkb:pomalidomide |
| gptkbp:replaces |
gptkb:1961
|
| gptkbp:reported_by |
many countries
|
| gptkbp:research_focus |
anti-inflammatory properties
immune modulation anti-angiogenic properties |
| gptkbp:safety_monitoring_program |
REMS program
S. T. E. P. S. program |
| gptkbp:side_effect |
rash
drowsiness constipation peripheral neuropathy thrombosis birth defects thromboembolism neutropenia teratogenicity |
| gptkbp:storage |
room temperature
|
| gptkbp:used_for |
morning sickness
treatment of multiple myeloma treatment of leprosy treating leprosy treating multiple myeloma |
| gptkbp:was_initially_thought_to_be |
safe and effective
|
| gptkbp:was_prescribed_to |
pregnant women
|
| gptkbp:was_withdrawn_from |
the market
|
| gptkbp:bfsParent |
gptkb:Celgene
|
| gptkbp:bfsLayer |
4
|